Eli Lilly and Company is trading 4.5% up at $1126.80 following strong premarket interest and persistent optimism surrounding its GLP-1 obesity and diabetes franchise.
- The upward move suggests institutional investors are engaging in dip-buying following a recent pullback, supported by a robust growth outlook and solid analyst backing.
- Shares are outperforming the broader markets, which remain mixed, as the company's market-leading position in the weight-loss drug sector continues to drive sentiment.